Correlation Between Verve Therapeutics and Eupraxia Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Verve Therapeutics and Eupraxia Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Verve Therapeutics and Eupraxia Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Verve Therapeutics and Eupraxia Pharmaceuticals Common, you can compare the effects of market volatilities on Verve Therapeutics and Eupraxia Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Verve Therapeutics with a short position of Eupraxia Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Verve Therapeutics and Eupraxia Pharmaceuticals.

Diversification Opportunities for Verve Therapeutics and Eupraxia Pharmaceuticals

0.34

Correlation Coefficient

Verve Therapeutics  Eupraxia Pharmaceuticals

Weak diversification

The 3 months correlation between Verve and Eupraxia is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Verve Therapeutics and Eupraxia Pharmaceuticals Commo in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eupraxia Pharmaceuticals and Verve Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Verve Therapeutics are associated (or correlated) with Eupraxia Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eupraxia Pharmaceuticals has no effect on the direction of Verve Therapeutics i.e., Verve Therapeutics and Eupraxia Pharmaceuticals go up and down completely randomly.

Pair Corralation between Verve Therapeutics and Eupraxia Pharmaceuticals

Given the investment horizon of 90 days Verve Therapeutics is expected to generate 1.64 times more return on investment than Eupraxia Pharmaceuticals. However, Verve Therapeutics is 1.64 times more volatile than Eupraxia Pharmaceuticals Common. It trades about 0.03 of its potential returns per unit of risk. Eupraxia Pharmaceuticals Common is currently generating about 0.02 per unit of risk. If you would invest  641.00  in Verve Therapeutics on October 7, 2024 and sell it today you would lose (17.00) from holding Verve Therapeutics or give up 2.65% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Verve Therapeutics  vs.  Eupraxia Pharmaceuticals Commo

Verve Therapeutics

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Verve Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Verve Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Eupraxia Pharmaceuticals

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Verve Therapeutics and Eupraxia Pharmaceuticals

The main advantage of trading using opposite Verve Therapeutics and Eupraxia Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Verve Therapeutics position performs unexpectedly, Eupraxia Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will offset losses from the drop in Eupraxia Pharmaceuticals' long position.

The idea behind Verve Therapeutics and Eupraxia Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.